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cost-effectiveness ratio (ICER). Other costs included in the model were obtained by 
the declared public budget of those Hospitals. RESULTS: The annual total therapy 
cost for etanercept, adalimumab and inﬂiximab per patient was $141,050, $158,938 
and $163,152 Mexican pesos, respectively. The ACR 70 rates responses of etanercept, 
adalimumab and inﬂiximab, indicated in clinical trials are 43%, 21% and 10% 
respectively. The ICER per additional patient achieving ACR 70 response of etanercept 
when compared with adalimumab was $81,309, and $66,976 when compared with 
inﬂiximab etanercept was a dominant alternative compared with adalimumab and 
inﬂiximab. CONCLUSIONS: According to published results, the use of etanercept in 
patients with RA is the most cost-saving alternative. If the use of etanercept is 
increased, more patients could have access to biologic therapy and the health care 
institutions in Mexico could contain costs in the treatment of RA.
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OBJECTIVES: Persistence with osteoporosis medications is a signiﬁcant clinical issue, 
with many patients discontinuing therapy after just one year. The purpose of this study 
was to estimate the lifetime clinical and economic impact of poor persistence among 
patients with osteoporosis in Brazil. METHODS: We used modeling techniques and 
data from secondary sources to quantify the impact on risks, costs, and consequences 
of hip fracture resulting from poor persistence with osteoporosis medications. All 
patients entering the model were assumed to be 65-year-old postmenopausal women, 
recently diagnosed with osteoporosis, and newly initiated on bisphosphonate therapy. 
The model calculates the risk of hip fracture as well as fracture-attributable life-years 
lost and health care costs (acute and follow-up). To estimate the impact of poor treat-
ment persistence on these measures, we contrasted model results for a scenario assum-
ing perfect compliance with therapy over each patient’s remaining years of life to 
another assuming all patients would discontinue therapy after one year. Analyses were 
performed for all patients and for a subgroup with more severe disease (t-score 2.5). 
All costs were expressed in 2006 Brazilian Reais (R$) and discounted at 5% per 
annum. RESULTS: We estimate that Brazilian patients who discontinue osteoporosis 
therapy after one year would experience 27.0 additional fractures per 100 patients, 
lose an average of nearly one year of life (0.968 fracture-attributable life years), and 
incur an average of R$3611 in additional costs of fracture-related care compared with 
perfectly compliant patients. Corresponding numbers for the subgroup of patients 
with severe osteoporosis are 35.5 additional fractures (per 100), 1.31 fracture-
 attributable life-years lost, and R$5,603 in fracture-related health care costs. 
 CONCLUSIONS: The lifetime clinical and economic consequences of poor persistence 
among osteoporosis patients in Brazil may be considerable. Programs to improve 
persistence with osteoporosis medications have the potential to beneﬁt patients and 
payers alike.
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COST-EFFECTIVENESS OF COLLAGEN-POLYVINYLPYRROLIDONE IN 
THE TREATMENT OF STABLE NONUNION TIBIAL FRACTURES
Idrovo J, Rivas R, Zapata L
Guia Mark, Mexico, DF, Mexico
OBJECTIVES: Traumatic fractures of the lower extremities often require prolonged 
rehabilitation or multiple procedures to achieve maximum functional recovery and, 
therefore, they are an area of substantial socioeconomic cost. Tibia fractures are the 
most common long bone fracture. Although only a relatively small percentage of the 
total of fractures—between 2% and 7%—are nonunion fractures, most of them (62%) 
affect the tibia. The aim of this analysis is to asses the cost-effectiveness of collagen-
polyvinylpyrrolidone versus surgical treatment with intra-medullar nailing in the man-
agement of nonunion tibial fractures, from the health care payer’s perspective. 
METHODS: A cost-effectiveness analysis was developed using a decision-tree model 
that simulates costs and effectiveness for a 12-month period. The effectiveness measure 
was the percentage of patients who shows radiographic fracture union at the end of 
the period of analysis. The comparators were collagen-polyvinylpyrrolidone versus 
surgical treatment with intramedullary nailing. Resource use and cost data were 
obtained from hospital records of patients being treated at a third-level hospital within 
the Mexican Social Security Institute (IMSS) and price lists and rates published by 
health institutions. Effectiveness data were obtained from international published 
 literature. Sensitivity analyses were performed to determine the results robustness. 
RESULTS: The expected costs of treatment for the alternatives were: US$2,467.3 for 
collagen-polyvinylpyrrolidone versus USD$7,920.6. Tibial fracture consolidation was 
present in 95.7% of the patients treated with intramedullary nailing and in 99.6% of 
the patients treated with collagen-polyvinylpyrrolidone. Incremental analysis shows 
collagen-polyvinylpyrrolidone as dominant alternative. CONCLUSIONS: Collagen-
polyvinylpyrrolidone is more effective and less expensive than intramedullary nailing 
for the management of patients with stable nonunion tibial fractures.
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OBJECTIVES: Knee osteoarthrosis is a multifactorial, progressive and incurable rheu-
matic ailment; most treatments look for a maximum recovery of mobility and func-
tionality of the knee joint, with a minimum risk possibility. Due to its high cost and 
invasive character, gonarthrosis surgical treatment is reserved, according to the clinical 
practice guidance available in Mexico, for severe pain and joint functionality limita-
tion cases; deﬁned as knee osteoarthrosis present in IV degree, or functional class III 
onwards. This study evaluates cost and effectiveness of the use of Hylan G-F 20 vs. 
intraarticular steroids to withhold surgery in patients with severe knee osteoarthrosis. 
METHODS: Cost-effectiveness analysis using a decision tree to simulate a hypotheti-
cal cohort behavior of patients with severe knee osteoarthrosis for a period of two 
years, from the perspective of the health service supplier. Costs were estimated using 
prices of 2008 and are expressed in US dollars (exchange rate of 11.14 pesos/1 US 
dollar). RESULTS: With Hylan G-F 20, 94.6 % of patients did not require surgery 
during the analysis period vs. 50%, in the case of those under intraarticular steroid 
treatment. Expected treatment costs: Hylan G-F 20, $2081.0, and intraarticular ste-
roids, $4593.2. The average cost-effectiveness of treatments: Hylan G-F 20, $2200.5 
and intraarticular steroids, $9111.6. Incremental analysis shows Hylan G-F 20 as 
dominant alternative. Different sensitivity analyses corroborate the dominance rela-
tionship exercised by Hylan G-F 20 over the steroid treatment. CONCLUSIONS: 
Hylan G-F 20 is a more effective and less expensive alternative than steroid treatment 
to withhold surgery in patients with severe knee osteoarthrosis.
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ESTUDIO FARMACOECONÓMICO DE LOS TRATAMIENTOS ACIDO 
ZOLEDRÓNICO, RISEDRONATO, ALENDRONATO E IBANDRONATO EN 
EL MANEJO DE LA OSTEOPOROSIS EN MUJERES POSMENOPÁUSICAS 
EN VENEZUELA.
Fernandez Y
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OBJETIVO: Análisis costo-efectividad de los tratamientos, Ácido Zoledrónico, Rise-
dronato, Alendronato e Ibandronato, en el manejo de la osteoporosis en posmenopáu-
sicas. Impacto de la adherencia a los tratamientos anuales y semanales para la 
osteoporosis, en términos de: número de fracturas de cadera, costos asociados a las 
fracturas de cadera y días de hospitalización. MÉTODOS: Retrospectivo, analítico. 
Información de efectividad a partir de ensayos clínicos, lo que representa un Nivel de 
evidencia I, grado de recomendación A. Los costos de medicamentos a precio de 
mercado y los costos hospitalarios a partir de una muestra representativa de centros 
de salud de complejidad mediana y alta en Venezuela. RESULTADOS: La relación 
costo-efectividad (costo-por incremento de 1% de la densidad mineral ósea) fue en el 
caso de cadera, para Acido Zoledrónico US$ 13,178, Alendronato US$ 15,521 e 
Ibandronato US$ 20,625. El costo de una fractura de cadera se estimó en US$ 34.884 
(hospitalización, cirugía, cuidados, prótesis, andadera, exámenes). De acuerdo a la 
población femenina venezolana, la prevalencia de padecer osteoporosis, los riesgos de 
fractura asociados a la adherencia a los tramientos y los costos, se estimó que el costo 
social de las fracturas de cadera estaría para el tratamiento semanal en US$ 1.015.984, 
para el anual en US$ 1.015–984 y sin tratamiento US$ 1.344.403. Los días de hospi-
talización se estimaron en: tratamiento semanal 116.500 días, anual 85.800 días y sin 
tratamiento en 154.158 días. CONCLUSIONES: Los tratamientos anuales para 
el manejo de la osteoporosis, debido a sus costos, efectividad y mayores niveles de 
adherencia representan una opción eﬁciente en el manejo de la osteoporosis. La mayor 
adherencia a los tratamientos permite reducir el número de fracturas y consumo de 
recursos sanitarios, permitiendo una contención de costos y una minimización de los 
costos de oportunidad al posibilitar un uso más eﬁciente de los recursos.
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OBJECTIVES: To analyse the cost-minimization of viscosupplmentation in compari-
son with arthroscopy/lavage for the treatment of moderate osteoarthritis of knee. 
METHODS: A cost-minimization analysis from the Brazilian Private Payer perspec-
tive, with a time horizon of 2 years was conduct. A decision tree considering the 
probabilities of treatment fail or success, were performed. Study comparators exam-
ined were Hyaluronic Acid (Synvisc©) and Arthroscopy with Lavage (Arthroscopy). 
The clinical aspects regarding beneﬁts and probabilities data were extracted from 
clinical trials and meta-analysis of clinical trials for the alternatives. The analysis was 
based on Brazilian current clinical practice. Treatment costs were collected from a 
private payer’s database. Costs and beneﬁts were validated by a panel of Brazilian 
specialists from payers. Due to short term analysis discounting was not applied, the 
results were converted in US Dollars (R$2.3/USD 1.00). A one-way sensitivity analysis 
was performed. RESULTS: Patients using Hyaluronic Acid get the lowest total cost 
per treatment (Synvisc©  USD 2,042 OR R$4.697; Arthroscopy  USD 2136 OR 
R$4.913). The results were sensitive to Hyaluronic Acid cost regarding all other 
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variables base case were robust in an interval of o 20%. CONCLUSIONS: Viscosup-
plementation is a cost-saving alternative for for the treatment of moderate osteoar-
thritis of knee compared to arthroscopy/lavage in the perspective of Brazilian’s Private 
Sector.
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OBJECTIVES: Assess RA health care resource utilization in a sample of Brazilian 
private health system beneﬁciaries. METHODS: Three Health Management Organiza-
tion (HMOs) databases were analyzed retrospectively, involving 1,057,033 people, 
corresponding to approximately 3% of total private health system beneﬁciaries in 
Brazil. The analysis was done in 35 months (from January 2004 to November 2007). 
The following health care resources were considered: clinical appointment, hospital-
ization, emergency service, drugs and laboratory exams. All RA patients were com-
pared to non-RA patients in terms of health care resource usage. RESULTS: From 
1,057,033 people analyzed, 4,817 (0.46%) were classiﬁed as having RA, being the 
prevalence rate among women and men 3.5: 1. Those patients concentrated 4.8% 
of the total costs of whole population analyzed. The cost per month/per member 
(cost pm/pm) of RA patients was 6.6 times higher than non-RA population. In addi-
tion, RA patients, compared to non-RA patients, demonstrated 3.4 and 13 times 
higher clinical appointments and hospitalization, respectively. Considering other 
chronic diseases (hypertension, heart failure, asthma, bronchitis and diabetes mellitus 
patients), RA patients demonstrated 1.4 and 3.1 times higher clinical appointments 
and hospitalization, respectively. Comorbiditidy was associated to 33% of RA 
patients, mainly cardiovascular disorders (CVD). CONCLUSIONS: Our results rein-
force the international literature data demonstrating that despite 0.46% prevalence, 
RA has high individual cost (concentrating 4.8% of total costs of whole population 
analyzed) due to multifactor variables, including pharmaceutical assistance and 
comorbidities. Regarding health care resources the study showed that RA patients 
had a higher utilization than non- RA patients, conﬁrming the literature about the 
important cost of the disease in the clinical practice. In addition we suggest an impor-
tant association between RA and comorbidities, especially CVD. In conclusion, RA 
may require speciﬁc strategies by decision makers to optimize its management and 
reduce cost.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To assess whether patients with rheumatoid arthritis (RA) who are 
newly initiated on tumor necrosis factor (TNF) antagonists adalimumab, etanercept, 
and inﬂiximab perceive differences in treatment outcomes. METHODS: Study data 
were derived from the 2006 RA Survey (Waves 7 and 8), a nationally (United States) 
representative survey of adults with RA conducted by Consumer Health Sciences 
International. Only patients currently taking TNF antagonists were included. Patients 
with prior self-reported TNF-antagonist use were excluded to avoid potential response 
bias. Responses to 19 questions on various aspects of treatment related to effective-
ness, safety, and patient convenience were collected and converted from an ordered-
response scale to a binary scale (1  favorable response [“strongly agree” or “agree”] 
vs. 0  nonfavorable response [“neither agree nor disagree,” “disagree,” or “strongly 
disagree”]). Chi-square tests identiﬁed signiﬁcant differences between treatments in 
the percentages of patients reporting favorable responses (p  0.05), and odds ratios 
(ORs) were determined using logistic regression, with controls for age and duration 
of RA. RESULTS: The study sample included 303 patients currently taking adalim-
umab (n  83), etanercept (n  133), or inﬂiximab (n  87). The odds of reporting 
favorable outcomes were approximately 2 times greater with adalimumab vs. etaner-
cept for convenience (OR  1.96), no long-term risks (OR  1.93), no short-term 
adverse effects (OR  1.84), symptom relief within 2 weeks (OR  1.98), and increased 
energy within 2 weeks (OR  2.29). The odds of reporting favorable outcomes with 
adalimumab vs. inﬂiximab were greater for convenience (OR  2.78,) and no long-
term risks (OR  2.27). The odds of reporting favorable outcomes with inﬂiximab vs. 
etanercept differed only for symptom relief within 2 weeks (OR  2.27) and increased 
energy within 2 weeks (OR  2.21, p  0.05 for all comparisons). CONCLUSIONS: 
RA patients initiating TNF-antagonist therapy perceived adalimumab to be more 
convenient than etanercept or inﬂiximab. Adalimumab was also perceived to offer 
rapid symptom relief and fewer risks compared with etanercept, and fewer long-term 
risks vs. inﬂiximab.
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OBJECTIVES: To examine the treatment effect of ustekinumab on physical disability 
and QoL in PsA patients using data from a phase II trial. METHODS: Patients with 
active PsA were randomized to ustekinumab 90mg/63mg (n  76) at wks0, 1, 2, and 
3, followed by placebo at wks12 and 16, or placebo at wks0, 1, 2, and 3, followed 
by ustekinumab 63mg at wks12 and 16 (n  70). Physical disability was assessed using 
the disability index from the HAQ (0:no difﬁculty to 3: unable to do) and DLQI 
(range: 0–30) assessed QoL. Clinically meaningful improvement was deﬁned as a 
0.25-point improvement in the disability index, and a 5-point improvement in the 
DLQI. Continuous variables were compared using ANOVA on the van der Waerden 
normal scores. Binary endpoints were compared using Chi-square test. RESULTS: 
Baseline PsA patients had moderate physical disability (mean disability index 1.0) and 
impaired QoL (mean DLQI 11.5). Ustekinumab-treated patients demonstrated signiﬁ-
cant improvement in physical disability as early as 1wk after the ﬁrst dose. After 4 
treatments at wks0, 1, 2 and 3, 60% of patients in the ustekinumab group vs. 28% 
in the placebo group achieved clinically meaningful improvement in disability (HAQ 
responders) at wk12 (p  0.001), and the mean reduction in disability index at wk12 
was 0.31 in the ustekinumab group vs. 0.04 in the placebo group (p  0.001). At 
wk12, 67.0% of HAQ responders maintained response through wk36. 60.3% of 
patients in the ustekinumab group vs. 23.6% in the placebo group achieved a clinically 
meaningful improvement in QoL (DLQI responders) at wk12 (p  0.001). At wk12, 
45.2% of DLQI responders in the ustekinumab group maintained response through 
wk36. Patients in the placebo group who crossed over to ustekinumab at wk12 and 
16 improved in disability and QoL at wk36 similar in magnitude to those initially 
randomized to ustekinumab. CONCLUSIONS: Ustekinumab signiﬁcantly improved 
physical disability and QoL in patients with PsA.
NEUROLOGICAL DISORDERS – Cost Studies
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OBJECTIVES: To determine the budget impact of incorporating levodopa/carbidopa/
entacapone FDC in Distrito Federal’s public reimbursement system for Parkinson 
disease treatment. METHODS: In present analysis, it was considered the quantity 
reimbursed for Distrito Federal in 2007 in Parkinson Disease treatment, based on 
DATASUS (National public health care database). Results were converted in US Dollars 
(R$2.27/USD 1.00). It was considered the medications costs used in Distrito Federal’s 
bidding: USD 0.04/tablet for both combinations of levodopa/carbidopa; USD 0.53/
tablet for both combinations of levodopa/benserazide; USD 0.95/tablet for entacapone. 
Levodopa/benserazide’s presentations have different prices, however to simplify the 
analysis, we took the price of the most used presentation (78% in units) and considered 
it for both. According to DATASUS, considering all levodopas’ combinations reim-
bursed in Distrito Federal in 2007, 62% was levodopa/carbidopa and 38% was 
levodopa/benserazide. The price of all levodopa/carbidopa/entacapone FDC’s were 
ﬁxed in USD 0.97/tablet. A one-way sensitivity analysis was performed. RESULTS: 
In Distrito Federal, the quantities reimbursed in 2007 for entacapone were 43,380 
and for all levodopas’ combinations were 395,510. Considering the prices used in 
Distrito Federal’s bidding, the total of expenses was US$131,311. In this scenario, if 
levodopa/carbidopa/entacapone FDC is used in the place of free dosage combinations, 
then the total of expenses was estimated in US$122,369. The sensitivity analysis on 
cost variables in an interval of o 20% was robust with the base analysis. CONCLU-
SIONS: This budget impact analysis showed a potential economy of US$8942 if 
levodopa/carbidopa/entacapone FDC is incorporated in Distrito Federal’s public reim-
bursement system. Besides, the use of FDC can provide higher adherence of patients 
to the treatment, once it is easier administrating one tablet instead of two or more; 
the patients prefer to take less quantity of tablets; the switches of dosage are easier.
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OBJECTIVES: To determine the budget impact of incorporating levodopa/carbidopa/
entacapone FDC in São Paulo’s public reimbursement system for Parkinson disease 
treatment. METHODS: In present analysis, it was considered the quantity reimbursed 
